Literature DB >> 18347013

The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells.

Punita Dhawan1, Yingjun Su, Yee Mon Thu, Yingchun Yu, Paige Baugher, Darrel L Ellis, Tammy Sobolik-Delmaire, Mark Kelley, Timothy C Cheung, Carl F Ware, Ann Richmond.   

Abstract

The pleiotropic transcription factor nuclear factor-kappaB (NF-kappaB (p50/p65)) regulates the transcription of genes involved in the modulation of cell proliferation, apoptosis, and oncogenesis. Furthermore, a host of solid and hematopoietic tumor types exhibit constitutive activation of NF-kappaB (Basseres, D. S., and Baldwin, A. S. (2006) 25, 6817-6830). However, the mechanism for this constitutive activation of NF-kappaB has not been elucidated in the tumors. We have previously shown that NF-kappaB-inducing kinase (NIK) protein and its association with Inhibitor of kappaB kinase alphabeta are elevated in melanoma cells compared with their normal counterpart, leading to constitutive activation of NF-kappaB. Moreover, expression of dominant negative NIK blocked this base-line NF-kappaB activity in melanoma cells. Of the three receptors that require NIK for activation of NF-kappaB, only the lymphotoxin-beta receptor (LTbeta-R) is expressed in melanoma. We show in this manuscript that for melanoma there is a strong relationship between expression of the LTbeta-R and constitutive NF-kappaB transcriptional activity. Moreover, we show that activation of the LTbeta-R can drive NF-kappaB activity to regulate gene expression that leads to enhanced cell growth. The inhibition by LTbeta-R shRNA resulted in decreased NF-kappaB promoter activity, decreased growth, and decreased invasiveness as compared with control. These results indicate that the LTbeta-R constitutively induces NF-kappaB activation, and this event may be associated with autonomous growth of melanoma cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18347013      PMCID: PMC2397477          DOI: 10.1074/jbc.M708272200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2.

Authors:  H Y Song; C H Régnier; C J Kirschning; D V Goeddel; M Rothe
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK.

Authors:  J D Woronicz; X Gao; Z Cao; M Rothe; D V Goeddel
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

3.  Constitutive expression and costimulatory function of LIGHT/TNFSF14 on human melanoma cells and melanoma-derived microvesicles.

Authors:  Roberta Mortarini; Alessia Scarito; Daisuke Nonaka; Marina Zanon; Ilaria Bersani; Elisabetta Montaldi; Elisabetta Pennacchioli; Roberto Patuzzo; Mario Santinami; Andrea Anichini
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

4.  LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator.

Authors:  D N Mauri; R Ebner; R I Montgomery; K D Kochel; T C Cheung; G L Yu; S Ruben; M Murphy; R J Eisenberg; G H Cohen; P G Spear; C F Ware
Journal:  Immunity       Date:  1998-01       Impact factor: 31.745

5.  Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1.

Authors:  S A Marsters; T M Ayres; M Skubatch; C L Gray; M Rothe; A Ashkenazi
Journal:  J Biol Chem       Date:  1997-05-30       Impact factor: 5.157

6.  MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1.

Authors:  N L Malinin; M P Boldin; A V Kovalenko; D Wallach
Journal:  Nature       Date:  1997-02-06       Impact factor: 49.962

7.  Lymphotoxin-beta receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kappaB.

Authors:  T L VanArsdale; S L VanArsdale; W R Force; B N Walter; G Mosialos; E Kieff; J C Reed; C F Ware
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

8.  Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation.

Authors:  Hema Rangaswami; Anuradha Bulbule; Gopal C Kundu
Journal:  J Biol Chem       Date:  2004-07-07       Impact factor: 5.157

9.  Deregulated Akt3 activity promotes development of malignant melanoma.

Authors:  Jill M Stahl; Arati Sharma; Mitchell Cheung; Melissa Zimmerman; Jin Q Cheng; Marcus W Bosenberg; Mark Kester; Lakshman Sandirasegarane; Gavin P Robertson
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

10.  Down-regulation of the tumor suppressor PTEN by the tumor necrosis factor-alpha/nuclear factor-kappaB (NF-kappaB)-inducing kinase/NF-kappaB pathway is linked to a default IkappaB-alpha autoregulatory loop.

Authors:  Sunghoon Kim; Claire Domon-Dell; Junghee Kang; Dai H Chung; Jean-Noel Freund; B Mark Evers
Journal:  J Biol Chem       Date:  2003-11-17       Impact factor: 5.157

View more
  14 in total

Review 1.  NF-κB addiction and its role in cancer: 'one size does not fit all'.

Authors:  M M Chaturvedi; B Sung; V R Yadav; R Kannappan; B B Aggarwal
Journal:  Oncogene       Date:  2010-12-20       Impact factor: 9.867

2.  Regulation of the leucocyte chemoattractant receptor FPR in glioblastoma cells by cell differentiation.

Authors:  Jian Huang; Keqiang Chen; Jiaqiang Huang; Wanghua Gong; Nancy M Dunlop; O M Zack Howard; Xiuwu Bian; Yuqi Gao; Ji Ming Wang
Journal:  Carcinogenesis       Date:  2008-11-26       Impact factor: 4.944

Review 3.  NF-κB inducing kinase: a key regulator in the immune system and in cancer.

Authors:  Yee Mon Thu; Ann Richmond
Journal:  Cytokine Growth Factor Rev       Date:  2010-08-03       Impact factor: 7.638

Review 4.  The good and the bad of chemokines/chemokine receptors in melanoma.

Authors:  Ann Richmond; Jinming Yang; Yingjun Su
Journal:  Pigment Cell Melanoma Res       Date:  2009-02-14       Impact factor: 4.693

Review 5.  NF-kappaB and cancer: how intimate is this relationship.

Authors:  Sahdeo Prasad; Jayaraj Ravindran; Bharat B Aggarwal
Journal:  Mol Cell Biochem       Date:  2009-10-08       Impact factor: 3.396

6.  Negative feedback regulation of NF-κB-inducing kinase is proteasome-dependent but does not require cellular inhibitors of apoptosis.

Authors:  Carolyn M Gray; Kelly A McCorkell; Srinivas K Chunduru; Mark A McKinlay; Michael J May
Journal:  Biochem Biophys Res Commun       Date:  2014-06-02       Impact factor: 3.575

7.  Induction of the alternative NF-κB pathway by lymphotoxin αβ (LTαβ) relies on internalization of LTβ receptor.

Authors:  Corinne Ganeff; Caroline Remouchamps; Layla Boutaffala; Cécile Benezech; Géraldine Galopin; Sarah Vandepaer; Fabrice Bouillenne; Sandra Ormenese; Alain Chariot; Pascal Schneider; Jorge Caamaño; Jacques Piette; Emmanuel Dejardin
Journal:  Mol Cell Biol       Date:  2011-09-06       Impact factor: 4.272

8.  Association between genetic variations in tumor necrosis factor receptor genes and survival of patients with T-cell lymphoma.

Authors:  Kan Zhai; Jiang Chang; Chen Wu; Ning Lu; Li-Ming Huang; Tong-Wen Zhang; Dian-Ke Yu; Wen Tan; Dong-Xin Lin
Journal:  Chin J Cancer       Date:  2012-05-24

9.  Role of Tertiary Lymphoid Structures (TLS) in Anti-Tumor Immunity: Potential Tumor-Induced Cytokines/Chemokines that Regulate TLS Formation in Epithelial-Derived Cancers.

Authors:  Erica M Pimenta; Betsy J Barnes
Journal:  Cancers (Basel)       Date:  2014-04-23       Impact factor: 6.639

Review 10.  Role of the Lymphotoxin/LIGHT System in the Development and Maintenance of Reticular Networks and Vasculature in Lymphoid Tissues.

Authors:  Theresa T Lu; Jeffrey L Browning
Journal:  Front Immunol       Date:  2014-02-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.